OBJECTIVE: This study analyzed the expression of integrins alpha(v)beta3 and alpha(v)beta5 in glioma tissue and focused on the periphery of high-grade gliomas. METHODS: The analysis was performed with Western blot, immunohistochemistry, and immunofluorescence, by use of two monoclonal antibodies able to recognize the functional integrin heterodimer. The expression of integrin-related ligands and growth factors also was studied. Sections from the tumor periphery were classified as either tumor periphery (light tumor infiltrate or scant visible cells) or peritumor (heavy tumor infiltration). RESULTS: Our data on glioma tissues demonstrated that both integrins were expressed in glioma cells and vasculature and their expression correlated with the histological grade. Alpha(v)beta3 expression was prominent in astrocytic tumors. Both integrins were markers of tumor vasculature, particularly of endothelial proliferation. A high-grade glioma periphery demonstrated a prominent expression of integrin alpha(v)beta3. Cells demonstrating alpha(v)beta3 positivity were identified as tumor astrocytes and endothelial cells by double imaging. The same cells were surrounded by some alpha(v)beta3 ligands and co-localized fibroblast growth factor 2. Matrix metalloproteinase 2 also was found to be co-localized with alpha(v)beta3 in the same cells. Alpha(v)beta3 expression was more relevant in tumor astrocytes. Alpha(v)beta3 integrin and vascular endothelial growth factor expression increased from the periphery to the tumor center. CONCLUSION: Our data support the role of integrins alpha(v)beta3 and alpha(v)beta5 in glioma-associated angiogenesis. In addition, they suggest a role for integrin alpha(v)beta3 in neoangiogenesis and cell migration in high-grade glioma periphery.
OBJECTIVE: This study analyzed the expression of integrins alpha(v)beta3 and alpha(v)beta5 in glioma tissue and focused on the periphery of high-grade gliomas. METHODS: The analysis was performed with Western blot, immunohistochemistry, and immunofluorescence, by use of two monoclonal antibodies able to recognize the functional integrin heterodimer. The expression of integrin-related ligands and growth factors also was studied. Sections from the tumor periphery were classified as either tumor periphery (light tumor infiltrate or scant visible cells) or peritumor (heavy tumor infiltration). RESULTS: Our data on glioma tissues demonstrated that both integrins were expressed in glioma cells and vasculature and their expression correlated with the histological grade. Alpha(v)beta3 expression was prominent in astrocytic tumors. Both integrins were markers of tumor vasculature, particularly of endothelial proliferation. A high-grade glioma periphery demonstrated a prominent expression of integrin alpha(v)beta3. Cells demonstrating alpha(v)beta3 positivity were identified as tumor astrocytes and endothelial cells by double imaging. The same cells were surrounded by some alpha(v)beta3 ligands and co-localized fibroblast growth factor 2. Matrix metalloproteinase 2 also was found to be co-localized with alpha(v)beta3 in the same cells. Alpha(v)beta3 expression was more relevant in tumor astrocytes. Alpha(v)beta3 integrin and vascular endothelial growth factor expression increased from the periphery to the tumor center. CONCLUSION: Our data support the role of integrins alpha(v)beta3 and alpha(v)beta5 in glioma-associated angiogenesis. In addition, they suggest a role for integrin alpha(v)beta3 in neoangiogenesis and cell migration in high-grade glioma periphery.
Authors: M Gelati; E Corsini; S Frigerio; B Pollo; G Broggi; D Croci; A Silvani; A Boiardi; A Salmaggi Journal: J Neurooncol Date: 2003-09 Impact factor: 4.130
Authors: Cuihong Jia; Matthew P Keasey; Hannah M Malone; Chiharu Lovins; Richard R Sante; Vlad Razskazovskiy; Theo Hagg Journal: Exp Neurol Date: 2018-11-06 Impact factor: 5.330
Authors: Oliver Schnell; Valerie Albrecht; David Pfirrmann; Sabina Eigenbrod; Bjarne Krebs; Alexander Romagna; Sebastian Siller; Armin Giese; Jörg-Christian Tonn; Christian Schichor Journal: Med Oncol Date: 2018-06-07 Impact factor: 3.064
Authors: L Burt Nabors; Karen L Fink; Tom Mikkelsen; Danica Grujicic; Rafal Tarnawski; Do Hyun Nam; Maria Mazurkiewicz; Michael Salacz; Lynn Ashby; Vittorina Zagonel; Roberta Depenni; James R Perry; Christine Hicking; Martin Picard; Monika E Hegi; Benoit Lhermitte; David A Reardon Journal: Neuro Oncol Date: 2015-03-11 Impact factor: 12.300
Authors: L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman Journal: J Clin Oncol Date: 2007-05-01 Impact factor: 44.544